Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]

Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][3] - The company has a clinical pipeline targeting two therapeutic areas: Medical Dermatology and Respiratory [3] Medical Dermatology - Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate for treating vitiligo, an autoimmune disorder [3] - The company also has EB01 (1.0% daniluromer cream), which is Phase 3-ready for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) [3] Respiratory - The most advanced respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome [3] - EB05 has received two funding awards from the Government of Canada to support its development [3] - Edesa is preparing an investigational new drug application (IND) for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis [3] Upcoming Events - Edesa will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto [1][2] - Management is scheduled to present on May 5 at 4:00pm ET [2]